Liu, Xihui http://orcid.org/0000-0002-9716-1032
Viswanadhapalli, Suryavathi http://orcid.org/0000-0002-7381-6962
Kumar, Shourya
Lee, Tae-Kyung
Moore, Andrew
Ma, Shihong
Chen, Liping
Hsieh, Michael http://orcid.org/0000-0002-9251-1101
Li, Mengxing
Sareddy, Gangadhara R. http://orcid.org/0000-0001-9977-3932
Parra, Karla
Blatt, Eliot B. http://orcid.org/0000-0002-9515-6547
Reese, Tanner C.
Zhao, Yuting
Chang, Annabel
Yan, Hui
Xu, Zhenming
Pratap, Uday P.
Liu, Zexuan
Roggero, Carlos M.
Tan, Zhenqiu
Weintraub, Susan T.
Peng, Yan
Tekmal, Rajeshwar R.
Arteaga, Carlos L. http://orcid.org/0000-0003-0870-9586
Lippincott-Schwartz, Jennifer
Vadlamudi, Ratna K. http://orcid.org/0000-0003-2849-4076
Ahn, Jung-Mo http://orcid.org/0000-0002-9104-525X
Raj, Ganesh V. http://orcid.org/0000-0001-5098-6347
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA223828-01, 1R01CA223828, 1R01CA179120-01, CA223828-01, R01CA223828)
Cancer Prevention and Research Institute of Texas (DP150096, DP150096, DP150096)
U.S. Department of Defense (W81XWH-18-1-0020, W81XWH-13-2-0093, W81XWH-12-1-0288)
Mays Cancer Center, UTHSCSA
Welch Foundation (AT-1595)
Dorothy and James Cleo Thompson foundation), the Mimi and John Cole foundation
Article History
Received: 8 April 2021
Accepted: 28 April 2022
First Online: 2 June 2022
Competing interests
: J.-M.A., G.V.R., X.L. and R.K.V. are joint holders on issued and pending patents on ERX-11 and ERX-41, which have been licensed to EtiraRx. G.V.R. serves, or has served, in an advisory role to Bayer, Johnson and Johnson, Myovant, EtiraRx, Amgen, Pfizer and Astellas. He has, or has had, grant support from Bayer, EtiraRx and Johnson and Johnson. C.L.A. serves, or has served, in an advisory role to Novartis, Merck, Lilly, Sanofi, Daiichi Sankyo, Puma, OrigiMed, AstraZeneca, Arvinas, TAIHO Oncology and Athenex. He also has minor stock options in Provista. He has, or has had, grant support from Lilly, Pfizer and Takeda. He also served on the Scientific Advisory Board of the Komen Foundation. The other authors declare no competing interests.